hepatitis b e antigens

Summary

Summary: A closely related group of antigens found in the plasma only during the infective phase of hepatitis B or in virulent chronic hepatitis B, probably indicating active virus replication; there are three subtypes which may exist in a complex with immunoglobulins G.

Top Publications

  1. ncbi Hepatitis B virus infection--natural history and clinical consequences
    Don Ganem
    Department of Microbiology and Immunology and the Howard Hughes Medical Institute, University of California, San Francisco, USA
    N Engl J Med 350:1118-29. 2004
  2. ncbi Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level
    Chien Jen Chen
    Graduate Institute of Epidemiology, College of Public Health, National Taiwan University, Taipei, Taiwan
    JAMA 295:65-73. 2006
  3. ncbi Predicting cirrhosis risk based on the level of circulating hepatitis B viral load
    Uchenna H Iloeje
    Global Epidemiology and Outcomes Research, Pharmaceutical Research Institute, Bristol Myers Squibb Company, Wallingford, Connecticut
    Gastroenterology 130:678-86. 2006
  4. ncbi A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B
    Ting Tsung Chang
    National Cheng Kung University Medical College, Tainan, Taiwan
    N Engl J Med 354:1001-10. 2006
  5. ncbi Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B
    George K K Lau
    Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong SAR, China
    N Engl J Med 352:2682-95. 2005
  6. ncbi Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B
    Ching Lung Lai
    Queen Mary Hospital, Hong Kong, China
    N Engl J Med 354:1011-20. 2006
  7. ncbi Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors
    Giovanna Fattovich
    Department of Surgical and Gastroenterological Sciences, University of Verona, Piazzale L A Scuro, 10, Verona 37134, Italy
    J Hepatol 48:335-52. 2008
  8. ncbi Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B
    E Jenny Heathcote
    University of Toronto, Toronto, Ontario, Canada
    Gastroenterology 140:132-43. 2011
  9. ncbi Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers
    Alexander J V Thompson
    Department of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, North Melbourne, Victoria, Australia
    Hepatology 51:1933-44. 2010
  10. ncbi Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues
    Florian van Bömmel
    Medizinische Klinik m S Hepatologie und Gastroenterologie Charité, Campus Virchow Klinikum, Universitatsmedizin Berlin, Germany
    Hepatology 51:73-80. 2010

Detail Information

Publications259 found, 100 shown here

  1. ncbi Hepatitis B virus infection--natural history and clinical consequences
    Don Ganem
    Department of Microbiology and Immunology and the Howard Hughes Medical Institute, University of California, San Francisco, USA
    N Engl J Med 350:1118-29. 2004
  2. ncbi Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level
    Chien Jen Chen
    Graduate Institute of Epidemiology, College of Public Health, National Taiwan University, Taipei, Taiwan
    JAMA 295:65-73. 2006
    ..Serum hepatitis B virus (HBV) DNA level is a marker of viral replication and efficacy of antiviral treatment in individuals with chronic hepatitis B...
  3. ncbi Predicting cirrhosis risk based on the level of circulating hepatitis B viral load
    Uchenna H Iloeje
    Global Epidemiology and Outcomes Research, Pharmaceutical Research Institute, Bristol Myers Squibb Company, Wallingford, Connecticut
    Gastroenterology 130:678-86. 2006
    ..Cirrhosis develops as a result of hepatic inflammation and subsequent fibrosis in chronic hepatitis B infection. We report on the relationship between hepatitis B viremia and progression to cirrhosis in chronic hepatitis B infection...
  4. ncbi A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B
    Ting Tsung Chang
    National Cheng Kung University Medical College, Tainan, Taiwan
    N Engl J Med 354:1001-10. 2006
    ..Entecavir is a potent and selective guanosine analogue with significant activity against hepatitis B virus (HBV)...
  5. ncbi Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B
    George K K Lau
    Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong SAR, China
    N Engl J Med 352:2682-95. 2005
    ....
  6. ncbi Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B
    Ching Lung Lai
    Queen Mary Hospital, Hong Kong, China
    N Engl J Med 354:1011-20. 2006
    ..Entecavir is a potent and selective antiviral agent that has demonstrated efficacy in phase 2 studies in patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B...
  7. ncbi Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors
    Giovanna Fattovich
    Department of Surgical and Gastroenterological Sciences, University of Verona, Piazzale L A Scuro, 10, Verona 37134, Italy
    J Hepatol 48:335-52. 2008
    ..There is a growing understanding of viral, host and environmental factors influencing disease progression, which ultimately could improve the management of chronic hepatitis B...
  8. ncbi Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B
    E Jenny Heathcote
    University of Toronto, Toronto, Ontario, Canada
    Gastroenterology 140:132-43. 2011
    ..We evaluated long-term efficacy and safety of TDF monotherapy in patients with chronic hepatitis B who were positive or negative for hepatitis B e antigen (HBeAg(+) or HBeAg(-))...
  9. ncbi Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers
    Alexander J V Thompson
    Department of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, North Melbourne, Victoria, Australia
    Hepatology 51:1933-44. 2010
    ..28, P = 0.01) and did not correlate with intrahepatic cccDNA nor total HBV DNA. Quantitative IHC for hepatocyte HBsAg confirmed a relationship with viral replication only in HBeAg-positive patients...
  10. ncbi Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues
    Florian van Bömmel
    Medizinische Klinik m S Hepatologie und Gastroenterologie Charité, Campus Virchow Klinikum, Universitatsmedizin Berlin, Germany
    Hepatology 51:73-80. 2010
    ..Loss of HBeAg occurred in 24% of patients and HBsAg loss occurred in 3%. No significant adverse events were noticed during TDF monotherapy...
  11. ncbi Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B
    Patrick Marcellin
    Service d Hepatologie, INSERM Unité 481, and Centre de Recherches Claude Bernard sur les Hépatites Virales, Hopital Beaujon, Clichy, France
    N Engl J Med 348:808-16. 2003
    ..In preclinical and phase 2 studies, adefovir dipivoxil demonstrated potent activity against hepatitis B virus (HBV), including lamivudine-resistant strains...
  12. ncbi Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus
    B J McMahon
    Viral Hepatitis Program, Alaska Native Medical Center, c/o Arctic Investigations Program, Centers for Disease Control and Prevention, 4055 Tudor Centre Drive, Anchorage, AK 99508-5932, USA
    Ann Intern Med 135:759-68. 2001
    ..CONCLUSION: In HBsAg-positive carriers, observed clearance of HBeAg was more than 70% during the first 10 years of follow-up...
  13. ncbi Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C
    Y F Liaw
    Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei, Taiwan
    Hepatology 54:1591-9. 2011
    ..Adverse events were typical of those associated with PEG-IFNα-2a...
  14. ncbi Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load
    Tai Chung Tseng
    Division of Gastroenterology, Department of Internal Medicine, Buddhist Tzu Chi General Hospital Taipei Branch, Taipei, Taiwan
    Hepatology 55:68-76. 2012
    ..2 (95% CI, 7.8-22.1) for HBsAg level <10 versus ≥ 1000 IU/mL. When compared to HBV DNA level by receiver operating characteristic curve analysis, HBsAg level served as a better predictor of both 5-year and 10-year HBsAg loss...
  15. ncbi Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir
    Jurriën G P Reijnders
    Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    J Hepatol 54:449-54. 2011
    ..We aimed to investigate serum hepatitis B surface antigen (HBsAg) levels in patients with chronic hepatitis B virus (HBV) infection during peginterferon (PEG-IFN) and entecavir (ETV) monotherapy...
  16. ncbi Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report
    Henry Lik Yuen Chan
    Department of Medicine and Therapeutics and Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong
    J Hepatol 55:1121-31. 2011
    ..In clinical practice, serum HBsAg level should be used together with, but not as a substitute for, HBV DNA...
  17. ncbi Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B
    Ting Tsung Chang
    Medical College, National Cheng Kung University, Tainan, Taiwan, ROC
    Hepatology 51:422-30. 2010
    ..4% (2/145) lost hepatitis B surface antigen (HBsAg) during study ETV-901. Through 5 years, entecavir resistance emerged in one patient. The safety profile of entecavir was consistent with previous reports...
  18. pmc A large population study of spontaneous HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection: implications for antiviral therapy
    M F Yuen
    Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong, China
    Gut 52:416-9. 2003
    ..In the present study we examined the clinical features and significance of HBeAg seroconversion and acute exacerbation in 3063 Chinese CHB patients...
  19. ncbi Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients
    Karsten Wursthorn
    Department of Gastroenterology, Hepatology, and Endocrinology, Hannover Medical School, Hannover, Germany
    Hepatology 52:1611-20. 2010
    ..In patients with subsequent HBsAg loss, viral antigens were already undetectable in liver biopsy samples after 1 year of treatment. This was associated with markedly enhanced antiviral T cell reactivity...
  20. ncbi High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load
    Tai Chung Tseng
    Division of Gastroenterology, Department of Internal Medicine, Buddhist Tzu Chi General Hospital Taipei Branch, Taipei, Taiwan
    Gastroenterology 142:1140-1149.e3; quiz e13-4. 2012
    ..Patients with lower levels of hepatitis B surface antigen (HBsAg) have higher chances of losing HBsAg than those with high levels. However, little is known about whether higher levels of HBsAg increase risk for HCC...
  21. ncbi The secreted hepatitis B precore antigen can modulate the immune response to the nucleocapsid: a mechanism for persistence
    D R Milich
    Department of Molecular Biology, The Scripps Research Institute, La Jolla, CA 92037, USA
    J Immunol 160:2013-21. 1998
    ....
  22. ncbi Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy
    Yun Fan Liaw
    Liver Research Unit, Medical College, Chang Gung University, Taipei, Taiwan
    J Gastroenterol Hepatol 18:246-52. 2003
    ..In conclusion, a better understanding of the pathogenetic mechanisms and natural course of hepatitis flares, wiser selection of patients and the timing of drug therapy are crucial to achieve better treatment results...
  23. ncbi Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients
    Chien Hung Chen
    Division of Hepatogastroenterology, Department of Internal Medicine, Chang Gung Memorial Hospital Kaohsiung Medical Center, Kaohsiung, Taiwan
    Gastroenterology 133:1466-74. 2007
    ....
  24. pmc Molecular and phylogenetic analyses suggest an additional hepatitis B virus genotype "I"
    Hai Yu
    National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiamen University, Xiamen, China
    PLoS ONE 5:e9297. 2010
    ..All evidence suggests that W29, together with other related strains found in Vietnam and Laos, should be classified into a new genotype...
  25. pmc A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen
    Margaret T Chen
    Karolinska Institute and Swedish Institute for Infectious Disease Control, 171 82 Solna, Sweden
    Proc Natl Acad Sci U S A 101:14913-8. 2004
    ..This HBeAg-mediated immune regulation may predispose to chronicity during perinatal infections and prevent severe liver injury during adult infections...
  26. ncbi Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia
    Tin Nguyen
    Department of Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, North Melbourne, Vic, Australia
    J Hepatol 52:508-13. 2010
    ..We aimed to define the serum HBsAg titres during the different phases of CHB in a cohort of Asian patients infected with either genotype B or C HBV...
  27. ncbi Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients
    Rami Moucari
    Service d Hepatologie, Hopital Beaujon, Clichy, France
    Hepatology 49:1151-7. 2009
    ..HBsAg loss was observed in three patients, all with SVR...
  28. pmc Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications
    M F Yuen
    Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam Rd, Hong Kong, China
    Gut 54:1610-4. 2005
    ..Identifying risk factors for the development of complications of chronic hepatitis B (CHB) is important for setting up treatment criteria...
  29. ncbi Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir
    Jung Min Lee
    Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
    Hepatology 53:1486-93. 2011
    ..The sensitivity and specificity were 75.0% and 89.8%, respectively, with a decline of 1.00 PE IU/mL at 6 months. With ETV therapy, the correlation between HBV DNA and qHBsAg peaked at 6 months in HBeAg(+) patients...
  30. ncbi Hepatitis B e antigen and the risk of hepatocellular carcinoma
    Hwai I Yang
    Graduate Institute of Epidemiology, College of Public Health, National Taiwan University, Taipei
    N Engl J Med 347:168-74. 2002
    ..We conducted a prospective study to determine the relation between positivity for hepatitis B surface antigen (HBsAg) and HBeAg and the development of hepatocellular carcinoma...
  31. pmc Impact of hepatitis B virus infection on human immunodeficiency virus response to antiretroviral therapy in Nigeria
    John Idoko
    Jos University Teaching Hospital, Jos, Plateau State, Nigeria
    Clin Infect Dis 49:1268-73. 2009
    ....
  32. ncbi Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection
    Hwai I Yang
    Genomics Research Center, Academia Sinica, Graduate Institute of Epidemiology, College of Public Health and Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Toronto, Ontario, Canada
    J Clin Oncol 28:2437-44. 2010
    ..This study aimed to develop nomograms for predicting hepatocellular carcinoma risk in patients with chronic hepatitis B...
  33. ncbi Poor durability of lamivudine effectiveness despite stringent cessation criteria: a prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients
    Feng Liu
    Department of Infectious Diseases and Hepatology, the Second Hospital of Shandong University, Shanghai, China
    J Gastroenterol Hepatol 26:456-60. 2011
    ..This study was designed to assess the durability of lamivudine treatment with stringent cessation criteria in hepatitis B e antigen (HBeAg)-negative patients and to explore potential predictive factors...
  34. pmc A large population histology study showing the lack of association between ALT elevation and significant fibrosis in chronic hepatitis B
    Wai Kay Seto
    Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong
    PLoS ONE 7:e32622. 2012
    ..We determined the association between various clinical parameters and significant liver injury in both hepatitis B e antigen (HBeAg)-positive and HBeAg-negative patients...
  35. ncbi Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: a systematic review
    George V Papatheodoridis
    2nd Department of Internal Medicine, Athens University Medical School, Hippokration General Hospital of Athens, Greece
    J Hepatol 57:196-202. 2012
    ..We systematically reviewed all the available histological data on HBeAg-negative patients with persistently normal ALT (PNALT) to determine the prevalence of significant liver disease and its associating factors...
  36. ncbi Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients
    Atsushi Ono
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Hepatol 57:508-14. 2012
    ..We determined the antiviral potency and viral resistance rate after 4 years of continuous entecavir treatment in patients with chronic hepatitis B (CHB) infection...
  37. ncbi Seroprevalence of hepatitis B infection during pregnancy and risk of perinatal transmission
    Manisha Dwivedi
    Department of Gastroenterology, Moti Lal Nehru Medical College, Allahabad, 211 001 India
    Indian J Gastroenterol 30:66-71. 2011
    ..To investigate the seroprevalence of hepatitis B surface antigen (HBsAg) in pregnant women and possible risk factors for perinatal hepatitis B virus (HBV) transmission...
  38. ncbi Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues
    Jurriën G P Reijnders
    Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Gravendijkwal 230, Room Ha 204, Rotterdam, The Netherlands
    J Hepatol 52:493-500. 2010
    ..Entecavir is a potent inhibitor of viral replication in nucleos(t)ide analogue (NA)-naïve chronic hepatitis B patients, but data on the efficacy in NA-experienced subjects are limited...
  39. pmc The risk of perinatal hepatitis B virus transmission: hepatitis B e antigen (HBeAg) prevalence estimates for all world regions
    Jördis J Ott
    World Health Organization, Geneva, Switzerland
    BMC Infect Dis 12:131. 2012
    ..The risk of developing chronic HBV infection and liver disease is highest at young age. Our aim was to assess perinatal HBV transmission risk by means of estimating age- and region-specific HBeAg prevalence...
  40. ncbi Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir
    C Q Pan
    Division of Liver Diseases, Department of Medicine, The Mount Sinai Medical Center, Mount Sinai School of Medicine, NY, USA
    J Viral Hepat 19:213-9. 2012
    ..TDF treatment was safe and well tolerated. In conclusion, suboptimal response to ETV is rare (approximately 3%). TDF monotherapy is safe and very effective in the management of HBV patients with SOR to ETV...
  41. ncbi Benign course of long-standing hepatitis B virus infection among Greenland Inuit?
    Henrik Bygum Krarup
    Department of Clinical Biochemistry, Aalborg Hospital, Aarhus University Hospital, Denmark
    Scand J Gastroenterol 43:334-43. 2008
    ..The role of the virus subtype is controversial. The purpose of this study was to characterize HBV infection in detail and its impact on general health, body-build and liver biochemistry...
  42. ncbi Serum hepatitis B virus-DNA levels correlate with long-term adverse outcomes in spontaneous hepatitis B e antigen seroconverters
    Tai Chung Tseng
    Department of Internal Medicine, Division of Gastroenterology, Buddhist Tzu Chi General Hospital Taipei Branch, Taipei, Taiwan
    J Infect Dis 205:54-63. 2012
    ....
  43. ncbi Clinical factors associated with liver stiffness in hepatitis B e antigen-positive chronic hepatitis B patients
    Grace Lai Hung Wong
    Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong SAR, China
    Clin Gastroenterol Hepatol 7:227-33. 2009
    ..We analyzed the clinical factors associated with advanced liver fibrosis in hepatitis B e antigen (HBeAg)-positive chronic hepatitis B patients...
  44. ncbi Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B
    R G Gish
    Division of Hepatology and Complex GI, Physicians Foundation California Pacific Medical Center, San Francisco, CA 94115 1932, USA
    J Viral Hepat 17:16-22. 2010
    ....
  45. ncbi Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa
    Erik H C J Buster
    Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
    Gastroenterology 137:2002-9. 2009
    ..We analyzed data from the 2 largest global trials of hepatitis B e antigen (HBeAg)-positive patients with chronic hepatitis B to determine which are most likely to respond to PEG-IFN-alfa therapy...
  46. ncbi Viral determinants of hepatitis B surface antigen seroclearance in hepatitis B e antigen-negative chronic hepatitis B patients
    Henry Lik Yuen Chan
    Department of Medicine and Therapeutics and Institute of Digestive Disease, The Chinese University of Hong Kong
    J Infect Dis 204:408-14. 2011
    ..We studied whether quantification of serum HBsAg and HBV DNA levels could predict spontaneous HBsAg clearance in patients with negative hepatitis B e antigen (HBeAg)...
  47. ncbi Influential factors of prognosis in lamivudine treatment for patients with acute-on-chronic hepatitis B liver failure
    Li Jie Sun
    Department of Infectious Diseases, Second Affiliated Hospital, Harbin Medical University, Harbin, China
    J Gastroenterol Hepatol 25:583-90. 2010
    ..In this study, the efficacy of lamivudine was investigated in patients with ACLF. The effects of HBV DNA load and its related factors on the prognosis were also further explored...
  48. ncbi Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B
    Milan J Sonneveld
    Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
    Gastroenterology 142:513-520.e1. 2012
    ..A limited number of patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B respond to treatment with peginterferon alfa (PEG-IFN). We investigated whether IL28B genotypes are associated with response...
  49. ncbi Analysis of clinical, biochemical and viral factors associated with early relapse after lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B patients in Taiwan
    Y H Huang
    Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, Tainan, Taiwan, Republic of China
    J Viral Hepat 10:277-84. 2003
    ..Most patients had biochemical relapse within 12 months after lamivudine treatment regardless of HBV genotype. A high pretreatment viral load is the determinant for early biochemical relapse...
  50. ncbi Large-scale survey of naturally occurring HBV polymerase mutations associated with anti-HBV drug resistance in untreated patients with chronic hepatitis B
    S Mirandola
    Venetian Institute of Molecular Medicine, Padova, Italy
    J Viral Hepat 18:e212-6. 2011
    ..These results confirm that HBV mutations, which confer resistance against currently available anti-HBV NAs, may already exist in patients who have never received the drug...
  51. ncbi Sequence variation upstream of precore translation initiation codon reduces hepatitis B virus e antigen production
    Sang Hoon Ahn
    Liver Research Center, Rhode Island Hospital and Brown Medical School, 55 Claverick Street, Providence, RI 02903, USA
    Gastroenterology 125:1370-8. 2003
    ..Most South African hepatitis B virus strains harbor point mutations immediately upstream of the precore AUG codon. The aim of this study was to determine their effect on hepatitis B e antigen expression...
  52. ncbi Emergence of entecavir-resistant mutations in nucleos(t)ide-naive Japanese patients infected with hepatitis B virus: virological breakthrough is also dependent on adherence to medication
    Hidehiro Kamezaki
    Department of Medicine and Clinical Oncology, Chiba University, Graduate School of Medicine, 1 8 1 Inohana, Chuo Ku, Chiba 260 8670, Japan
    Scand J Gastroenterol 46:1111-7. 2011
    ....
  53. ncbi Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters
    Tai Chung Tseng
    Division of Gastroenterology, Department of Internal Medicine, Buddhist Tzu Chi General Hospital Taipei Branch, Taipei, Taiwan
    Gastroenterology 141:517-25, 525.e1-2. 2011
    ..However, little is known about factors predicting HBsAg loss in patients who spontaneously clear hepatitis B e antigen (HBeAg)...
  54. ncbi Hepatitis B virus e antigen downregulates cytokine production in human hepatoma cell lines
    Shuang Wu
    Department of Medicine and Clinical Oncology, Chiba University, Graduate School of Medicine, Chiba, Japan
    Viral Immunol 23:467-76. 2010
    ..HBeAg might modify disease progression by inhibiting inflammatory cytokine and IFN gene expression, while simultaneously suppressing NF-κB-signaling- and IFNß-promoter activation...
  55. ncbi Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B
    Edward J Gane
    New Zealand Liver Unit, Auckland City Hospital, Auckland, New Zealand
    Liver Int 31:676-84. 2011
    ..In the GLOBE trial, telbivudine demonstrated superior efficacy to lamivudine at 2 years in patients with chronic hepatitis B (CHB)...
  56. ncbi Bioinformatic analysis of the hepadnavirus e-antigen and its precursor identifies remarkable sequence conservation in all orthohepadnaviruses
    Peter Revill
    Victorian Infectious Diseases Reference Laboratory, North Melbourne, Australia
    J Med Virol 82:104-15. 2010
    ..Whilst much of this sequence conservation was within key immunomodulatory epitopes, highest conservation was observed at the unique HBeAg N-terminus, suggesting this sequence in particular may play an important role in HBeAg function...
  57. ncbi Elimination of immunodominant epitopes from multispecific DNA-based vaccines allows induction of CD8 T cells that have a striking antiviral potential
    Petra Riedl
    Department of Internal Medicine I, University of Ulm, Germany
    J Immunol 183:370-80. 2009
    ..Subdominant epitopes in vaccines can hence prime specific CD8 T cell immunity in a tolerogenic milieu that delivers specific antiviral effects to HBV-expressing hepatocytes...
  58. ncbi HBV DNA level as an important determinant of E antigen seroconversion of chronic hepatitis B during adefovir dipivoxil therapy
    Kuo Chih Tseng
    Department of Internal Medicine, Buddhist Dalin Tzu Chi General Hospital, Chiayi, Taiwan
    Hepatogastroenterology 56:813-8. 2009
    ..The study was to evaluate which clinical or virological variables correlate with endpoints (e.g. HBeAg seroconversion and HBV DNA <10(5) copies/mL) during Adefovir dipivoxil or placebo therapy...
  59. ncbi Clinical significance and evolution of core promoter and precore mutations in HBeAg-positive patients with HBV genotype B and C: a longitudinal study
    Chien Hung Chen
    Division of Hepatogastroenterology, Chang Gung University College of Medicine, Kaohsiung, Taiwan
    Liver Int 27:806-15. 2007
    ....
  60. ncbi Natural history of chronic hepatitis B in Euro-Mediterranean and African countries
    Stephanos J Hadziyannis
    Department of Medicine and Hepatology, Henry Dunant Hospital, Athens, Greece
    J Hepatol 55:183-91. 2011
    ....
  61. ncbi Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study
    Jessica Liu
    Rollins School of Public Health, Emory University, Atlanta, Georgia, USA
    Gastroenterology 139:474-82. 2010
    ..Few studies have explored the incidence and determinants of spontaneous seroclearance using a long-term follow-up study. This study aimed to examine the natural history and predictors of HBsAg seroclearance...
  62. ncbi A case-control study for differences among hepatitis B virus infections of genotypes A (subtypes Aa and Ae) and D
    Yasuhito Tanaka
    Department of Clinical Molecular Informative Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
    Hepatology 40:747-55. 2004
    ..In conclusion, the clearance of HBeAg from serum may occur by different mechanisms in HBV/Aa, HBV/Ae, and HBV/D infections, which may influence clinical manifestations in the Western countries where both genotypes A and D are prevalent...
  63. ncbi Perinatal transmission of hepatitis B virus: an Australian experience
    Elke Wiseman
    Liverpool Hospital, Sydney South West Area Health Service, Sydney, NSW, Australia
    Med J Aust 190:489-92. 2009
    ..To determine the rate of perinatal hepatitis B virus (HBV) transmission in an Australian setting and to identify maternal virological factors associated with highest risk of transmission...
  64. pmc Genotypes and clinical phenotypes of hepatitis B virus in patients with chronic hepatitis B virus infection
    Jia Horng Kao
    Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei, Taiwan
    J Clin Microbiol 40:1207-9. 2002
    ..002). In conclusion, patients with genotype C infection have a more aggressive clinical phenotype than do those with genotype B infection, which contributes to the former group's progressive liver disease and poor clinical outcomes...
  65. ncbi Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis
    Fasiha Kanwal
    Veterans Affairs Greater Los Angeles Healthcare System, David Geffen School of Medicine at University of California, Los Angeles, and Center for the Study of Digestive Healthcare Quality and Outcomes, Los Angeles, California 90073, USA
    Ann Intern Med 142:821-31. 2005
    ..Interferon has clinically significant side effects, and lamivudine is associated with viral resistance. In contrast, adefovir is safe and has lower viral resistance but is more expensive. The most cost-effective approach is uncertain...
  66. ncbi Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time
    Dar In Tai
    Liver Research Unit, Chang Gung Memorial Hospital, Chung Gung University College of Medicine, Taipei, Taiwan
    Hepatology 49:1859-67. 2009
    ....
  67. ncbi Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B
    Maria Buti
    Servicio de Hepatologi a, Hospital Vall d Hebrón and Ciber ehd del Instituto Carlos III, Barcelona, Spain
    J Hepatol 51:640-6. 2009
    ..The aim of this study was to estimate the cost-effectiveness of the oral antiviral treatments lamivudine, adefovir, telbivudine, entecavir and tenofovir, in patients with CHB...
  68. ncbi Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death
    Jin De Chen
    Department of Internal Medicine, Bei Hu Branch, National Taiwan University Hospital, Taipei, Taiwan
    Gastroenterology 138:1747-54. 2010
    ..The risk and the predictors of liver disease progression in carriers of inactive hepatitis B virus (HBV) are unclear...
  69. ncbi Prevalence and mother-to-infant transmission of hepatitis viruses B, C, and E in Southern Tanzania
    C Menendez
    Unidad de Epidemiologia y Bioestadistica, Institut d Investigacions Biomedicas August Pi i Sunyer IDIBAPS, Hospital Clinic, Barcelona, Spain
    J Med Virol 58:215-20. 1999
    ..The results of this study show for the first time in Africa that mother-to-infant transmission does not play a significant role in the acquisition of HCV infection...
  70. ncbi Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection
    David Milich
    Vaccine Research Institute of San Diego, San Diego, CA 92109, USA
    Hepatology 38:1075-86. 2003
    ..These dual roles of the HBeAg and its ability to activate or tolerize T cells show the complexity of the interactions between the HBeAg and the host during HBV infection...
  71. ncbi Hepatitis B e antigen seroconversion: a critical event in chronic hepatitis B virus infection
    Yun Fan Liaw
    Liver Research Unit, Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Taipei, 105, Taiwan
    Dig Dis Sci 55:2727-34. 2010
    ..The importance of HBeAg seroconversion is underscored by current CHB treatment guidelines that recommend limiting the duration of antiviral therapy in HBeAg-positive patients who achieve seroconversion...
  72. ncbi Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients
    Tassilo Volz
    Department of Medicine, University Hospital Hamburg Eppendorf, Hamburg, Germany
    Gastroenterology 133:843-52. 2007
    ....
  73. ncbi Quantitative assessment of the antiviral potencies of 21 shRNA vectors targeting conserved, including structured, hepatitis B virus sites
    Dianxing Sun
    Bethune International Peace Hospital, Departmrnt of Liver Disease, 398 West Zhongshan Road, 050082 Shijiazhuang, PR China
    J Hepatol 52:817-26. 2010
    ..The aim of this study was to provide such information...
  74. ncbi Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B
    Emmet B Keeffe
    Stanford University School of Medicine, Stanford, California 94304 1509, USA
    Clin Gastroenterol Hepatol 5:890-7. 2007
    ..Future studies of the use of the roadmap concept in improving outcomes of chronic hepatitis B are warranted...
  75. ncbi Telbivudine versus lamivudine in patients with chronic hepatitis B
    Ching Lung Lai
    University Department of Medicine, Queen Mary Hospital, Hong Kong, China
    N Engl J Med 357:2576-88. 2007
    ..Reducing hepatitis B virus (HBV) replication to minimal levels is emerging as a key therapeutic goal for chronic hepatitis B...
  76. ncbi Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection
    Chi Jen Chu
    Department of Medicine, Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, MI, USA
    Hepatology 36:1408-15. 2002
    ..Given the fluctuating course of HBeAg-negative chronic hepatitis, it is not possible to define a single cutoff HBV DNA value for differentiating inactive carriers from patients with HBeAg-negative chronic hepatitis...
  77. ncbi Role of hepatitis B, C, and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference
    R Jardi
    Department of Biochemistry, Hospital Universitario Vall d Hebron, Barcelona, Spain
    Hepatology 34:404-10. 2001
    ..The reciprocal inhibition of viral replication seemed to be little influenced by the inherent genomic factors studied...
  78. ncbi Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B
    Yi Cheng Chen
    Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei, Taiwan
    Hepatology 51:435-44. 2010
    ..7% [P < 0.0001], 42.9% [P <0.0001], and 7.7% [P = 0.29], respectively). The hazard ratio of HBeAg-negative hepatitis, cirrhosis, and HCC was 2.95, 17.6, and 5.22, respectively, in group C compared with group A...
  79. ncbi Frequency and clinical outcomes of flares related to nucleos(t)ide analogue therapy in patients with chronic hepatitis B
    N P Zhang
    Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
    J Viral Hepat 18:e252-7. 2011
    ..In this study, flares related to NA therapy never led to immune control and sustained disease remission, and sometimes resulted in decompensated liver disease...
  80. ncbi Virological and clinical implication of core promoter C1752/V1753 and T1764/G1766 mutations in hepatitis B virus genotype D infection in Mongolia
    Abeer Elkady
    Department of Clinical Molecular Informative Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
    J Gastroenterol Hepatol 23:474-81. 2008
    ..The aim of the present study was to reveal virological and clinical features of hepatitis B virus (HBV) genotype D infection...
  81. ncbi A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone
    Henry Lik Yuen Chan
    Chinese University of Hong Kong and Alice Ho Miu Ling Nethersole Hospital, Hong Kong, China
    Ann Intern Med 142:240-50. 2005
    ..Conventional interferon and lamivudine monotherapy are unsatisfactory in treating hepatitis B virus (HBV) infection...
  82. ncbi Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis
    D L Veenstra
    Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, WA 98195, USA
    Aliment Pharmacol Ther 27:1240-52. 2008
    ..Several anti-viral treatments are now available for HBeAg-negative chronic hepatitis B (CHB), but the clinical and economic outcomes of potential treatment strategies and durations are unclear...
  83. ncbi On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients
    Wei Cai
    Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, People s Republic of China
    J Clin Virol 48:22-6. 2010
    ..Telbivudine is one of the most frequently used antiviral drug at the current stage, but its long-term effectiveness, particularly at off-treatment, is still unclear...
  84. ncbi Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV-hepatitis B virus-infected patients
    Sarah Maylin
    Laboratoire de Virologie, Hopital Saint Louis, AP HP, Paris, France
    AIDS 26:939-49. 2012
    ..Although their quantification is useful for other antivirals, such has not been the case with tenofovir disoproxil fumarate (TDF), particularly in HIV infection...
  85. ncbi HBV genotypes: relevance to natural history, pathogenesis and treatment of chronic hepatitis B
    Beom Kyung Kim
    Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea
    Antivir Ther 16:1169-86. 2011
    ..Hence, in this article, we review the global epidemiology and the natural history of HBV infection, with emphasis on summarizing the different HBV genotypes according to regions...
  86. ncbi Quantitative analysis of HBV DNA level and HBeAg titer in hepatitis B surface antigen positive mothers and their babies: HBeAg passage through the placenta and the rate of decay in babies
    Zhanhui Wang
    Department of Infectious Disease, Nanfang Hospital, The First Medical College of PLA, Guangzhou 510 515, China
    J Med Virol 71:360-6. 2003
    ..HBV DNA levels in hepatitis B carrier mothers are associated with the failure of HBIG and vaccine immunization, and the additional influence of transmitted HBeAg cannot be excluded...
  87. ncbi Nucleotide divergences in the core promoter and precore region of genotype D hepatitis B virus in patients with persistently elevated or normal ALT levels
    A M Bozdayi
    Ankara University, Institute of Hepatology, School of Medicine, Department of Gastroenterology, 06100 Cebeci, Ankara, Turkey
    J Clin Virol 21:91-101. 2001
    ....
  88. ncbi Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial
    Harry L A Janssen
    Department of Gastroenterology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands
    Lancet 365:123-9. 2005
    ..Treatment of HBeAg-positive patients with chronic hepatitis B is not effective in most. A combination of immunomodulatory pegylated interferon alfa-2b and antiviral lamivudine might improve the rate of sustained response...
  89. ncbi Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion
    Patrick Miailhes
    Hotel Dieu, Service d hépatologie et de gastroentérologie, Lyon, France
    Clin Infect Dis 45:624-32. 2007
    ....
  90. ncbi Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT
    Manoj Kumar
    Department of Gastroenterology, G B Pant Hospital, New Delhi, India
    Gastroenterology 134:1376-84. 2008
    ..We studied the ALT, HBV DNA levels, and spectrum of histologic lesions in such patients...
  91. ncbi Comparison of full genome sequences between two hepatitis B virus strains with or without preC mutation (A1896) from a single Korean hepatocellular carcinoma patient
    Hong Kim
    Department of Microbiology and Immunology, Liver Research Institute, College of Medicine, Seoul National University, Seoul 110 799, Korea
    J Microbiol Biotechnol 17:701-4. 2007
    ....
  92. ncbi Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels
    Vincent Rijckborst
    Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands
    Hepatology 52:454-61. 2010
    ..74). None of the 20 patients (20% of the study population) in whom a decrease in serum HBsAg levels was absent and whose HBV DNA levels declined less than 2 log copies/mL exhibited an SR (negative predictive value = 100%)...
  93. pmc Hepatitis B virus genotype C takes a more aggressive disease course than hepatitis B virus genotype B in hepatitis B e antigen-positive patients
    Henry Lik Yuen Chan
    Department of Medicine and Therapeutics, Chinese University of Hong Kong, Hong Kong SAR, People s Republic of China
    J Clin Microbiol 41:1277-9. 2003
    ..Disease activity was greater in patients infected by HBV genotype C than in those infected by HBV genotype B in the HBeAg-positive phase but not after HBeAg seroconversion...
  94. ncbi Natural history of hepatitis B virus infection: an update for clinicians
    Surakit Pungpapong
    Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Mayo Clin Proc 82:967-75. 2007
    ....
  95. ncbi Viral genotype and hepatitis B virus DNA levels are correlated with histological liver damage in HBeAg-negative chronic hepatitis B virus infection
    Henry Lik Yuen Chan
    Department of Medicine, The Chinese University of Hong Kong
    Am J Gastroenterol 97:406-12. 2002
    ..We aimed to study the relationship between the hepatitis B virus (HBV) genotypes, core promoter/precore stop codon mutations, and histological liver damage among hepatitis B e antigen (HBeAg)-negative patients...
  96. ncbi Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F
    Stephen E Livingston
    Liver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, Alaska
    Gastroenterology 133:1452-7. 2007
    ..Five hepatitis B virus genotypes were identified in Alaska Native persons; we analyzed clearance of HBeAg by age and genotype...
  97. ncbi Relationship of clinical and virological factors with hepatitis activity in hepatitis B e antigen-negative chronic hepatitis B virus-infected patients
    Joseph J Y Sung
    Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong
    J Viral Hepat 9:229-34. 2002
    ..Patient demographics, viral mutants or genotypes failed to predict disease activity. Hence, serum ALT and HBV DNA levels offer the best prediction of natural course of HBeAg-negative chronic HBV infection...
  98. ncbi Epidemiologic and virologic characteristics of hepatitis B virus genotype B having the recombination with genotype C
    Fuminaka Sugauchi
    Department of Internal Medicine and Molecular Science and Clinical Molecular Informative Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
    Gastroenterology 124:925-32. 2003
    ..Hepatitis B virus (HBV) isolates of genotype B (HBV/B) with or without the recombination with genotype C over the precore region plus core gene have been reported...
  99. pmc Modulation of the CD8+-T-cell response by CD4+ CD25+ regulatory T cells in patients with hepatitis B virus infection
    Ornella Franzese
    Institute of Hepatology, University College London, 69 75 Chenies Mews, London WC1E 6HX, United Kingdom
    J Virol 79:3322-8. 2005
    ..The possible role of CD4+ CD25+ T cells in the pathogenesis of chronic HBV infection is not supported by these data. However, these results might have implications for optimizing future immunotherapeutic approaches to HBV treatment...
  100. ncbi The oncogenic potential of hepatitis B virus rtA181T/ surface truncation mutant
    Ming Wei Lai
    Department of Pediatric Gastroenterology, Chang Gung Memorial Hospital, Taipei, Taiwan
    Antivir Ther 13:875-9. 2008
    ..Surprisingly, this patient has never received lamivudine or adefovir antiviral therapy. Here, we aimed to evaluate the oncogenic potential of HBV rtA181T/surface truncation mutant...
  101. ncbi The role of serial measurement of serum HBV DNA levels in patients with chronic HBeAg(-) hepatitis B infection: association with liver disease progression. A prospective cohort study
    George Zacharakis
    Unit of Preventive Medicine, Social Security Institute, Alexandroupolis, Greece
    J Hepatol 49:884-91. 2008
    ..To evaluate the fluctuating course of serum HBV-DNA levels during the natural history of chronic HBV infection in the general population of North-Eastern Greece, in association with liver disease progression...

Research Grants15

  1. VIRAHEP-C Clinical Center
    Anna Lok; Fiscal Year: 2005
    ..abstract_text> ..
  2. RECURRENT HEPATITIS B AFTER LIVER TRANSPLANTATION
    Anna Lok; Fiscal Year: 2007
    ..abstract_text> ..
  3. U.T. SOUTHWESTERN ADULT AIDS CLINICAL TRIALS UNIT
    Mamta Jain; Fiscal Year: 2008
    ..abstract_text> ..
  4. Natural Killer T Cells in an animal model of hepatitis C
    Margaret Koziel; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable] [unreadable] [unreadable]..
  5. COLORECTAL CANCER SCREENING IN HIGH RISK INDIVIDUALS
    Roshan Bastani; Fiscal Year: 2001
    ..Secondary analysis will examine the predictive value of our theoretical framework in modeling adherence behavior and psychological distress. Cost effectiveness of the intervention will also be assessed. ..
  6. DEVELOPMENT OF THE HBCAG AS A VACCINE CARRIER PLATFORM
    David Milich; Fiscal Year: 2008
    ..abstract_text> ..
  7. Liver Disease and HIV-HBV Coinfection in the HAART era
    Chloe Thio; Fiscal Year: 2008
    ..Given the experience of the investigative team and the well-characterized cohorts involved, the results from this proposal will yield insights into the management of HIV-HBV co-infected patients. ..
  8. Development of Glypican-3 as a biomarker for hepatocellular carcinoma
    Samuel So; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  9. Informed Decision Making Regarding PSA Screening
    Roshan Bastani; Fiscal Year: 2007
    ..abstract_text> ..
  10. T Lymphocyte Apoptosis in Hepatitis C Persistence
    Margaret Koziel; Fiscal Year: 2006
    ..abstract_text> ..
  11. Development of Preventative and Therapeutic HCV Vaccines
    David Milich; Fiscal Year: 2006
    ..It is anticipated that a NS3/4A DNA vaccine may be used for prophylactic or therapeutic applications either alone or in combination with E2-WHcAg hybrid particles. ..
  12. HCV VARIANTS AND IMMUNE RESPONSE IN INJECTION DRUG USERS
    Teresa Wright; Fiscal Year: 2004
    ..Finally, with the establishment of this cohort, we will be able to store serum and lymphocytes for future analysis of genetic determinants of viral persistence/clearance. ..
  13. Hepatitis B treatment and HIV Infection in resources limited settings
    Chloe L Thio; Fiscal Year: 2010
    ..This proposal has a high likelihood for success given the investigative team's experience, the randomized clinical trial design, and the nesting in an existing study. ..
  14. Suppression of Hepatoma Cell Growth by Celecoxib
    Ke Qin Hu; Fiscal Year: 2004
    ..abstract_text> ..
  15. Modulation of HBV Replication by the Immunoproteasome
    Michael Robek; Fiscal Year: 2006
    ..These studies may provide a better understanding of the host factors that modulate HBV replication and that ultimately determine the outcome of infection. ..